Abstract:We recently reported a group of lipopeptide-based membrane fusion inhibitors with potent antiviral activities against human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus (SIV). In this study, the in vivo therapeutic efficacy of such a lipopeptide, LP-52, was evaluated in rhesus macaques chronically infected with pathogenic SIVmac239. In a pilot study with one monkey, monotherapy with low-dose LP-52 rapidly reduced the plasma viral loads to below the limit of detection and maintained viral suppression during three rounds of structurally interrupted treatment. The therapeutic efficacy of LP-52 was further verified in four infected monkeys; however, three out of the monkeys had viral rebounds under the LP-52 therapy. We next focused on characterizing SIV mutants responsible for the in vivo resistance. Sequence analyses revealed that a V562A or V562M mutation in the N-terminal heptad repeat (NHR) and a E657G mutation in the C-terminal heptad repeat (CHR) of SIV gp41 conferred high resistance to LP-52 and cross-resistance to the peptide drug T20 and two newly designed lipopeptides (LP-80 and LP-83). Moreover, we showed that the resistance mutations greatly reduced the stability of diverse fusion inhibitors with the NHR site, and V562A or V562M in combination with E657G could significantly impair the functionality of viral envelopes (Envs) to mediate SIVmac239 infection and decrease the thermostability of viral six-helical bundle (6-HB) core structure. In conclusion, the present data have not only facilitated the development of novel anti-HIV drugs that target the membrane fusion step, but also help our understanding of the mechanism of viral evolution to develop drug resistance.IMPORTANCE The anti-HIV peptide drug T20 (enfuvirtide) is the only membrane fusion inhibitor available for treatment of viral infection; however, it exhibits relatively weak antiviral activity, short half-life, and a low genetic barrier to inducing drug resistance. Design of lipopeptide-based fusion inhibitors with extremely potent and broad antiviral activities against divergent HIV-1, HIV-2, and SIV isolates have provided drug candidates for clinical development. Here, we have verified a high therapeutic efficacy for the lipopeptide LP-52 in SIVmac239-infected rhesus monkeys. The resistance mutations selected in vivo have also been characterized, providing insights into the mechanism of action of newly designed fusion inhibitors with a membrane-anchoring property. For the first time, the data show that HIV-1 and SIV can share a similar genetic pathway to develop resistance, and that a lipopeptide fusion inhibitor could have a same resistance profile as its template peptide.

Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket

Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket

Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket

Two M-T Hook Residues Greatly Improve the Antiviral Activity and Resistance Profile of the HIV-1 Fusion Inhibitor SC29EK

Mutations of Gln64 in the HIV-1 Gp41 N-Terminal Heptad Repeat Render Viruses Resistant to Peptide HIV Fusion Inhibitors Targeting the Gp41 Pocket

An Artificial Peptide-Based Hiv-1 Fusion Inhibitor Containing M-T Hook Structure Exhibiting Improved Antiviral Potency and Drug Resistance Profile

ST103 HIV-1 Variants with Mutations in the Gp41 Pocket Region Are Resistant to HIV Fusion Inhibitors with Pocket-Binding Domain, but Sensitive to T20

HIV-1 Variants with a Single-Point Mutation in the Gp41 Pocket Region Exhibiting Different Susceptibility to HIV Fusion Inhibitors with Pocket- or Membrane-Binding Domain.

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41

Approaches for Identification of HIV-1 Entry Inhibitors Targeting Gp41 Pocket.

The binding mode of fusion inhibitor T20 onto HIV-1 gp41 and relevant T20-resistant mechanisms explored by computational study.

Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014)

HIV Entry Inhibitors Targeting Gp41: from Polypeptides to Small-Molecule Compounds

HIV-1 Gp41 Fusion Intermediate: a Target for HIV Therapeutics.

The M-T Hook Structure Increases the Potency of HIV-1 Fusion Inhibitor Sifuvirtide and Overcomes Drug Resistance.

Potent Hiv Fusion Inhibitors Against Enfuvirtide-Resistant Hiv-1 Strains

Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques

In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to Sifuvirtide, a Novel HIV-1 Fusion Inhibitor

High Throughput Screening and Characterization of HIV-1 Entry Inhibitors Targeting Gp41: Theories and Techniques.

Enfuvirtide (T20)-Based Lipopeptide is A Potent Hiv-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition